NCT05411718View on ClinicalTrials.gov

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
T CellsColorectal CancerLynch Syndrome
Interventions
DRUG

Naproxen

Given by PO

DRUG

Aspirin

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER